Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it will report financial results and operational highlights for the second quarter of 2026 before hosting a conference call and webcast at 8:30 a.m. ET on Aug. 10, 2026. A replay of the webcast will be available in the Investors section of the company’s website following the event, according to a press release.
The upcoming earnings call comes at a pivotal time for Tonix, which recently received FDA approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. This approval marks a significant milestone for the company and for patients suffering from fibromyalgia, a chronic condition characterized by widespread pain and fatigue. With TONMYA now on the market, analysts will be closely watching initial sales figures and market adoption during the second-quarter report.
Tonix is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA, the company’s CNS commercial infrastructure supports its marketed acute migraine products, Zembrace SymTouch and Tosymra. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder, which could expand its use significantly.
In addition, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder. The company is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The financial results will provide investors with insight into the company’s revenue streams from TONMYA and its migraine products, as well as research and development spending on its pipeline candidates. For the broader biotech industry, Tonix’s progress underscores the potential for repurposing existing drugs for new indications, as seen with TONMYA’s exploration in depression and stress disorders.
The company’s ability to generate revenue from its recently approved product while advancing multiple clinical programs will be a key focus for stakeholders. The conference call will offer details on operational highlights and future guidance.
For more information, visit the company’s newsroom at https://ibn.fm/TNXP and the full press release at https://ibn.fm/A9CfR.
